Omniab, Inc. · NASDAQ:OABI
Omniab — Q1 2023 Earnings Presentation
17 slides from Omniab's earnings presentation, May 11, 2023
Slide 1: Q1 2023 Financial Results & Business Update
1 Q1 2023 Financial Results & Business Update Nasdaq: OABI May 11, 2023
Slide 2: Disclaimer
2 Disclaimer We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business stra
Slide 3: Introduction
Omni > Introduction : Matt Foehr
Slide 4: Our Business
4 Our Business LEVERAGING OUR PROPRIETARY DISCOVERY TECHNOLOGY PLATFORM WORLDWIDE Industry’s Only 4-Species Platform One of the Largest Greenfields in the Pharma Industry Transgenic animals for fully human and bispecific POISED FOR $279 billion total addressable GROWTH market for antibodies by 2025
Slide 5: Active Partners
5 Active Partners Q1 2023: 70 ACTIVE PARTNERS Number of Active Partners 70 60 • New license and revenue sharing agreement signed in Q1 with Scripps 50 • Strong annual growth in key performance indicators continues, net of 40 attrition 30 ‒ Active Partners: ̴ 18% CAGR 2016 through 2022 20 • Partner p
Slide 6: Active Programs
6 Active Programs OUR PARTNERS CONTINUE TO START NEW PROGRAMS 301 Active Programs Number of Active Programs as of 03/31/2023 • Number of active programs reached 301 (net of attrition) ‒ Active Programs: ̴ 25% CAGR 2016 through 2022 • Clinical and pre-clinical matriculation of programs continues, and
Slide 7: Active Clinical Programs and Approved Products
7 Active Clinical Programs and Approved Products NEW CLINICAL ENTRANT IN Q1 2023 Number of Active Clinical Programs and Approved Products 30 • New program entered the clinic in Q1 2023 25 ‒ SGN-BB228 (Seagen): Anti-CD228 x 4-1BB Anticalin 20 • Based on dialog with partners, we see potential for appr
Slide 8: Q1 2023 and Recent Updates
8 Q1 2023 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM Batoclimab IMVT-1402 SGN-BB228 FcRn FcRn CD228x4-1BB • An investigational • Ongoing studies in: • Next-gen FcRn antagonist costimulatory bispecific • Myasthenia Gravis (P3) • Immunovant expects molecule composed
Slide 9: Launching OmniDeep at PEGS-Boston
9 Launching OmniDeep at PEGS-Boston PRESENTING ON MAY 17TH OmniDeep is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb, Inc.’s various technologies and capabilities. These tools include structural modeling, large multi-species antibody databases
Slide 10: Our Key Areas of Focus Going Forward
10 Our Key Areas of Focus Going Forward WE BELIEVE WE ARE WELL-POSITIONED FOR FUTURE GROWTH WHILE WE MAKE AN ENDURING AND SIGNIFICANT IMPACT ON THE INDUSTRY AND GLOBAL HUMAN HEALTH We Leverage a Highly Scalable Business where Investments in Technologies and Innovation are Informed by Discovery Relat
Slide 11: Financial Updates
11 Financial Updates Kurt Gustafson
Slide 12: First Quarter 2023 Financial Results
12 First Quarter 2023 Financial Results ($ Millions) Q1 2023 Q1 2022 Variance License and milestone revenue $ 12.6 $ 4.1 $ 8.5 Service revenue 4.0 5.3 (1.3) Royalty revenue 0.3 0.3 0.1 Total revenues 16.9 9.6 7.3 Research & development 13.8 10.8 3.0 General & administrative 8.2 4.1 4.1 Amortization
Slide 13: Balance Sheet Summary
13 Balance Sheet Summary March 31, December 31, in Millions 2023 2022 ASSETS Current assets: Cash & investments $ 113.6 $ 88.3 Accounts receivable, net 1.8 30.3 Other current assets 5.7 6.4 Goodwill & intangible assets 248.3 251.2 PPE & leases 40.3 41.5 Other assets 3.3 3.6 Total assets $ 413.0 $ 42
Slide 14: Quarterly Results
14 Quarterly Results ($ Millions) Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 License and milestone revenue $ 4.1 $ 2.3 $ 1.4 $ 31.1 $ 12.6 Service revenue 5.3 4.7 4.9 3.9 4.0 Royalty revenue 0.3 0.1 0.6 0.4 0.3 Total revenues 9.6 7.2 6.9 35.3 16.9 Research & development 10.8 11.5 13.2 12.9 13.8 General & ad
Slide 15: Q&A
Omni Q&A
Slide 16: Omni >
Omni >
Slide 17: Approved and Clinical-Stage Partner Pipeline as of 03/31/2023
17 Approved and Clinical-Stage Partner Pipeline as of 03/31/2023 THREE APPROVED PRODUCTS AND 24 ACTIVE CLINICAL-STAGE ANTIBODIES Partner Program Source Animal Therapy Area Target Phase 1 Phase 2 Phase 3 Registration Approved Zimberelimab OmniRat Oncology PD-1 Sugemalimab OmniRat Oncology PD-L1 Tecli